Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This study is a Phase I, intravenous, single-dose escalation study to evaluate the safety,
tolerability, pharmacokinetics and pharmacodynamics of PZ-128 (pepducin inhibitor of PAR1) in
subjects with vascular disease or who have 2 or more coronary artery disease (CAD) risk
factors.
Phase:
Phase 1
Details
Lead Sponsor:
Tufts Medical Center
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) Sinai Hospital of Baltimore